Clin2
NCT07332663Possibly a fitNot yet recruiting

New injection for relapsed B-cell blood cancers

B Cell Malignancies

Part of Blood & lymphatic, Cancer clinical trials.

This trial tests a new medicine called WGb-0301, given by injection, for people with certain blood cancers (B-cell lymphoma or lymphocytic leukemia) that have come back or not improved with other treatments. The goal is to see if this drug can help control the cancer and what side effects it might cause.

Summary written for real people, not researchers, by Clin2.

Phase
Early Phase 1
Enrollment
9 people
Ages
18 years to 70 years
Study type
Interventional

Who can take part

  • You must be between 18 and 70 years old.
  • Your cancer (B-cell lymphoma or lymphocytic leukemia) must have a marker called CD19 on it.
  • You should have tried standard treatments or your doctor says there are no standard options left.
  • You must be in good physical shape (able to do daily activities) and have a life expectancy of more than 3 months.
  • You must not have had CAR T-cell therapy or gene-modified T-cell treatments before.
  • You must not be pregnant or breastfeeding, and you must use reliable birth control during and for a while after the trial.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07065279Recruiting
JY231 injection for relapsed B-cell blood cancers

This trial tests a new treatment, JY231, for people with B-cell blood cancers that have come back or not responded to other treatments. It aims to see if this therapy can help when other options have stopped working.

Kunming, Yunnan
NCT07362732Not yet recruiting· Early Phase 1
Study of a new injection for relapsed multiple myeloma

This study tests an investigational injection called WGb-0302 for people with multiple myeloma that has come back or not responded to standard treatments. The goal is to see if it is safe and helpful, possibly by targeting a protein on the cancer cells called BCMA.

NCT07493174Not yet recruiting· Phase 1
Testing a new drug for B-cell blood cancers that have returned

This trial tests a new experimental medicine (SYS6055 injection) for people with B-cell blood cancers (leukemia or lymphoma) that have come back or not responded to standard treatments. The goal is to see if it is safe and how well it works against cancer cells that have the CD19 marker.

NCT07349823Not yet recruiting· Early Phase 1
New injection for autoimmune diseases that haven't responded to treatment

This trial tests an experimental injection (called WGb-0301) to see if it can help people with autoimmune diseases like lupus or scleroderma that have not improved with usual treatments. The goal is to find a new option for those who have run out of standard therapies.

NCT07240974Recruiting· Early Phase 1
Study of ZZSW-01 for B-cell blood cancers that returned or didn't respond

This trial tests a new drug called ZZSW-01 for people with certain B-cell blood cancers (like lymphoma or leukemia) that have come back or haven't gotten better after other treatments. It aims to see if the drug is safe and works against these cancers.

Wuhan
NCT07584850Not yet recruiting· Early Phase 1
GI001 therapy for relapsed or refractory B-cell lymphoma

This trial tests a new cell therapy called GI001 for patients with certain types of B-cell lymphoma or leukemia that have returned or not responded to previous treatments. It aims to see if this therapy can help control the disease.

Hear when a new B Cell Malignancies trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.